September 11, 2024
OXFORD, UK and CLEVELAND, Ohio, US, 11th September 2024 – The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership between the University of Oxford, UK and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, aimed at driving cutting-edge rare disease breakthroughs, announces the...
Continue Reading
April 12, 2023
Harrington Scholar Dr. Khvorova and research team have developed a technology to deliver gene therapy directly to lung tissue through intranasal administration, a development that could potentially create a new class of treatments for lung disease. Continue Reading
February 23, 2023
UVA Health School of Medicine scientists have discovered an unknown contributor to harmful blood vessel growth in the eye that could lead to new treatments for blinding macular degeneration and other common causes of vision loss. Continue Reading
February 14, 2023
Studies published from researchers at the biotech startup AcuraStem and the University of Southern California validated two potential drug targets in animal models of both genetic and sporadic ALS, paving the way for broad treatments. Continue Reading
February 10, 2023
Investigators discovered that a specific complex drives cell proliferation in different forms of blood cancers called mutated myeloproliferative neoplasms (MPNs), suggesting the complex could serve as an ideal therapeutic target for blood cancer. Continue Reading
February 08, 2023
In an international, multicenter, pivotal Phase 3 trial, a single under-the-skin injection of a biological drug given to patients within seven days of the onset of COVID-19 symptoms cut the likelihood they needed to be hospitalized in half. Continue Reading
November 22, 2022
Travis Dunckley, PhD, University of Arizona, 2016 ADDF-Harrington Scholar and team have developed a candidate drug they hope may successfully block the development or advancement of Alzheimer’s disease in Down syndrome patients. Continue Reading
October 19, 2022
PIC Therapeutics has closed a $35 million Series A financing round centered around the advancement of its lead asset, a novel therapeutic for advanced metastatic breast cancer. Continue Reading
August 18, 2022
Harrington Scholar developing a universal treatment to prevent and treat influenza A. Continue Reading
August 15, 2022
Licensing IP for SIK Inhibitors to Radius Health Continue Reading
August 09, 2022
Development of an exercise wearable to help personalize exercise and minimize the risks of dementia. Continue Reading